Cambridge Healthtech Institute’s 15th Annual
Antibodies for Cancer Therapy
Driving Breakthrough Therapies
May 12-13, 2025
The field of antibody therapy for cancer continues to evolve rapidly, with groundbreaking innovations pushing the boundaries of treatment efficacy and precision. The Antibodies for Cancer Therapy conference will showcase cutting-edge developments, and explore exciting new frontiers including radiopharmaceuticals, antibody-PROTAC conjugates, T cell engagers, and antibody-cytokine fusions. We will also examine the developability and optimization of biotherapeutics using in silico and pharmacological modeling, to look at immunogenicity risk profiles and PK modulation. By fostering collaborations and sharing insights on therapeutic antibody development, we hope to bring the industry together to drive more breakthroughs in antibody-based therapies.
Coverage will include, but is not limited to:
- Advances in Antibody-Based Therapies
- Radiopharmaceuticals/radioconjugates
- Antibody-PROTAC conjugates
- T cell engagers
- Antibody-cytokine fusions/antibody-cytokine mimetics
- Optimization and Development of Therapeutic Antibodies - Using in silico or pharmacological modeling for
- Developability assessment
- Immunogenicity risk profiling
- PK modulation
- Lessons Learned from Successful and Failed/Halted Antibody Therapeutics Development
The deadline for priority consideration is October 11, 2024.
AAll proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: